• LLY507 for Reproducible SMYD2 Assays

  2026-08-11

  A scenario-driven guide to using LLY507 (SKU B6119) in cell viability, proliferation, cytotoxicity, and mechanistic SMYD2 experiments. It connects product specifications with practical controls, dose-response design, data interpretation, and independent renal-fibrosis evidence.

• RWJ 67657: Precision p38 MAPK Workflows

  2026-08-11

  RWJ 67657, also known as JNJ-3026582, combines selective p38α/p38β inhibition with a workflow suited to cytokine, phosphorylation, and inflammatory-model studies. Its value is greatest when TNF-alpha suppression is measured alongside pathway activity, cell viability, and preserved T-cell function.

• How In Vitro Drug Response Metrics Shape Cancer Studies

  2026-08-10

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their timing, the study provides a more precise framework for interpreting drug responses and designing follow-up experiments.

• DiR (DiIC 18 (7)) for Membrane Tracking

  2026-08-09

  DiR (DiIC 18 (7)) enables low-background membrane tracking across live cells, fixed tissues, neuronal tracing, and biomimetic nanomedicine workflows. This practical guide connects membrane fluorescence with the trypsin-responsive pancreatitis platform while separating validated study findings from assay recommendations.

• Entecavir Workflows for HBV Research

  2026-08-08

  Build reproducible HBV replication assays around Entecavir, from DMSO stock preparation and dose-response design to resistant-strain testing and orthogonal viral endpoints. The workflow also translates a large postoperative HCC cohort into practical choices for interpreting antiviral data without confusing clinical association with laboratory mechanism.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-08-07

  Protect protein abundance and phosphorylation-dependent signals from the moment a sample is lysed. This EDTA-free 100X formulation is especially useful for macrophage signaling, HMGB1 post-translational modification studies, phosphoproteomics, and metal-sensitive biochemical assays.

• i-Motif Hairpin ASO Prodrugs for pH-Responsive Antitumor The

  2026-08-07

  This study presents a rationally designed antisense oligonucleotide (ASO) prodrug system using i-motif-based hairpin structures, enabling pH-triggered release and enhanced gene silencing in MYCN-amplified cells. The findings highlight significant advances in the structure-activity relationship of stimulus-responsive nucleic acid therapeutics for targeted cancer treatment.

• Ibrexafungerp Activity Against Echinocandin-Resistant Candid

  2026-08-06

  This study evaluates the in vitro efficacy of ibrexafungerp (MK 3118) against a large, genotypically and phenotypically characterized set of echinocandin-resistant Candida clinical isolates. Findings illuminate ibrexafungerp’s activity spectrum, highlight resistance nuances, and help define its potential place in antifungal therapy for invasive candidiasis.

• Applied Workflows with JNJ-26854165 (Serdemetan) in Cancer R

  2026-08-06

  JNJ-26854165 (Serdemetan) is a next-generation HDM2 inhibitor that enables precise p53 pathway activation, yielding superior anti-proliferative and apoptosis-inducing effects in preclinical cancer models. This article delivers stepwise protocols, troubleshooting strategies, and advanced use-cases—empowering oncology labs to maximize reproducibility and translational impact.

• Biotin-tyramide: Practical Guide for Signal Amplification Wo

  2026-08-05

  Biotin-tyramide is a high-purity biotin phenol reagent tailored for tyramide signal amplification in immunohistochemistry (IHC) and in situ hybridization (ISH). It addresses the need for precise and sensitive target detection but is not intended for diagnostic or live-cell applications due to its mechanism and formulation requirements.

• Amplifying Discovery: Cy3 TSA Fluorescence in Translational

  2026-08-05

  This thought-leadership article provides mechanistic insight and strategic guidance for translational researchers aiming to transcend the sensitivity limits of conventional immunohistochemistry, immunocytochemistry, and in situ hybridization. By contextualizing the Cy3 TSA Fluorescence System Kit within recent advances—such as the endothelial-centric paradigm of doxorubicin-induced cardiotoxicity—the article weaves evidence-based rationale, practical protocol recommendations, and a forward-looking perspective to empower precision biomolecular visualization.

• Partial BACE1 Inhibition Reduces Amyloid Beta Without Synapt

  2026-08-04

  Satir et al. (2020) demonstrated that moderate inhibition of BACE1—reducing amyloid beta (Aβ) production by up to 50%—does not impair synaptic transmission in cultured neurons. This finding refines the therapeutic window for BACE inhibitor strategies in Alzheimer's disease research, suggesting that partial enzyme inhibition may mitigate amyloid pathology without compromising neuronal communication.

• ABT-263 (Navitoclax): Optimizing Apoptosis Assays in Cancer

  2026-08-04

  ABT-263 (Navitoclax) is redefining apoptosis assay workflows with its high specificity for Bcl-2 family proteins, enabling precise cell death modulation in cancer biology. New delivery strategies, like galactose-functionalized micelle carriers, are enhancing selectivity and reducing off-target effects—empowering researchers to design safer, more effective experimental protocols.

• Neurotensin (CAS 39379-15-2): GPCR Trafficking & miRNA Regul

  2026-08-03

  Neurotensin is a validated 13-amino acid neuropeptide and Neurotensin receptor 1 activator. It enables reproducible studies of GPCR trafficking mechanisms and miRNA regulation in gastrointestinal models. This article outlines the molecular rationale, key evidence, and practical workflows for deploying Neurotensin (CAS 39379-15-2) in contemporary cell signaling research.

• ETS1 Orchestrates Mitophagy Regulation in BPD via SENP2/HSPA

  2026-08-03

  This study identifies ETS1 as a pivotal transcriptional regulator that suppresses mitochondrial damage-induced autophagy in bronchopulmonary dysplasia (BPD) by modulating the SENP2/HSPA8/FUNDC1 axis. These mechanistic insights reveal new molecular targets for BPD intervention and provide a framework for investigating chaperone-mediated autophagy in lung injury.

15810 records 1/1054 page Next 12345 下5页 Last page